Hot flushes in women with breast cancer: state of the art and future perspectives

References

• Kronenberg F. Hot flashes: epidemiology and physiology. Ann. NY Acad. Sci. 592, 52–86, discussion 123–133 (1990).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin. Proc. 77, 1207–1218 (2002).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J. Clin. Oncol. 16 501–514 (1998).
   PubMed Web of Science ®Google Scholar
• Harris PF, Remington PL, Trentham-Dietz, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J. Pain Symptom. Manage. 23, 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Wardlaw SL, Wehrenberg WB, Ferin M, Antunes JL, Frantz AG. Effects of sex steroids on β-endorphin in hypophysial portal blood. J. Clin. Endocrinol. Metab. 55, 877–881 (1982).
   PubMed Web of Science ®Google Scholar
• Freedman RR, Norton D, Woodward S, Cornélissen G. Core body temperatutre and circadian rhythm of hor flushes in menopausalm women. J. Clin. Endocrinol. Metab. 80, 2354–2358 (1995).
   PubMed Web of Science ®Google Scholar
• Berendsen HH. The role of serotonine in hot flushes. Maturitas 36, 155–164 (2000).
   PubMed Web of Science ®Google Scholar
• Befort CA, Klemp J. Sequelae of breast cancer and the influence of menopausal status at diagnosis among rural breast cancer survivors. J. Womens Health. 20, 1307–1313 (2011).
   Google Scholar
• Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J. Clin. Oncol. 21, 4184–4193 (2003).
   PubMed Web of Science ®Google Scholar
• Ganz PA. Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century. Am. J. Med. 118, 136–141 (2005).
   PubMedGoogle Scholar
• Mao JJ, Chung A, Benton A et al.Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol. Drug Saf. 22, 256–262 (2013).
   PubMed Web of Science ®Google Scholar
• Biglia N, Cozzarella M, Cacciari F et al.Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 45, 29–38 (2003).
   PubMed Web of Science ®Google Scholar
• Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J. Clin. Oncol. 13, 2737–2744 (1995).
   PubMed Web of Science ®Google Scholar
• Angelopoulos N, Barbounis V, Livadas S, Kaltsas D, Tolis G. Effects of estrogen deprivation due to breast cancer treatment. Endocr. Relat. Cancer 11, 523–535 (2004).
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J. Natl Cancer Inst. 94, 652–661 (2002).
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH et al.Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 126, 529–537 (2011).
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM et al.Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475–482 (2008).
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol. 6, 687–695 (2005).
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent J, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst. Rev. 18, CD002978 (2004).
   Google Scholar
• Letendre I, Lopes P. Menopause and oncologic risks. J. Gynecol. Obstet. Biol. Reprod. 41(Suppl. 7), 33–37 (2012).
   Google Scholar
• Holmberg L, Andersson H. HABITS (hormonal replacement therapy after breast cancer –is it safe?), a randomised comparison: trial stopped. Lancet 363, 453–455 (2004).
   PubMed Web of Science ®Google Scholar
• von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J. Natl Cancer Inst. 97, 533–535 (2005).
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM et al.Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475–482 (2008).
   PubMed Web of Science ®Google Scholar
• Fahlén M, Fornander T, Johansson H et al.Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer 49, 52–59 (2013).
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM et al.Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 10, 135–146 (2009).
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP et al.Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95(Suppl. 1), 1–66 (2010).
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. Structure-Function-Relationships, farmacokinetics and potency of progestins in treatment of the postmenopausal women. In: Treatment of the Postmenopausal Women: Basic and Clinical Aspects (2nd Edition). Lobo RA (Ed.). Lippincott, Williams and Wilkins, Philadelphia, PA, USA, 105–124 (1999).
   Google Scholar
• Gundersen S, Kvinnsland S, Lundgren S et al.Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 17, 45–50 (1990).
   PubMed Web of Science ®Google Scholar
• Andersen J, Kamby C, Ejlertsen B et al.Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol. 47, 718–724 (2008).
   PubMed Web of Science ®Google Scholar
• Abrams JS, Parnes H, Aisner J. Current status of high-dose progestins in breast cancer. Semin. Oncol. 17, 68–72 (1990).
   PubMedGoogle Scholar
• Goodwin JW, Green SJ, Moinpour CM et al.Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: southwest oncology group study 9626. J. Clin. Oncol. 26, 1650–1656 (2008).
   PubMed Web of Science ®Google Scholar
• Bertelli G, Venturini M, Del Mastro L et al.Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flushes in breast cancer patients: a randomized study. Ann. Oncol. 13, 883–888 (2002).
   PubMed Web of Science ®Google Scholar
• Barton D, Loprinzi C, Quella S, Sloan J, Pruthi S, Novotny P. Depomedroxyprogesterone acetate for hot flashes. J. Pain Symptom. Manage. 24, 603–607 (2002).
   PubMed Web of Science ®Google Scholar
• Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84, 4559–4565 (1999).
   PubMed Web of Science ®Google Scholar
• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA 284, 691–694 (2000).
   PubMedGoogle Scholar
• Nelson HD, Vesco KK, Haney E et al.Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295, 2057–2071 (2006).
   PubMed Web of Science ®Google Scholar
• Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 9, 227–234 (1987).
   PubMed Web of Science ®Google Scholar
• Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int. J. Womens Health 2, 123–135 (2010).
   PubMedGoogle Scholar
• Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flushes. J. Clin. Oncol. 29, 3842–3846 (2011).
   PubMedGoogle Scholar
• Loprinzi CL, Sloan J, Stearns V et al.Newer antidepressants and gabapentin for hot flushes: an individual patient pooled analysis. J. Clin. Oncol. 27, 2831–2837 (2009).
   PubMed Web of Science ®Google Scholar
• Barton DL, LaVasseur BI, Sloan JA et al.Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flushes: NCCTG trial N05C9. J. Clin. Oncol. 28, 3278–3283 (2010).
   PubMed Web of Science ®Google Scholar
• Archer DF, Dupont CM, Constantine GD et al.Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am. J. Obstet. Gynecol. 200, 238 e1–e10 (2009).
   PubMedGoogle Scholar
• Loprinzi CL, Pisansky TM, Fonseca R et al.Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J. Clin. Oncol. 16, 2377–2381 (1998).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA et al.Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356, 2059–2063 (2000).
   PubMed Web of Science ®Google Scholar
• Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet. Gynecol. 105, 161–166 (2005).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Levitt R, Barton D et al.Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7. J. Clin. Oncol. 24, 1409–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Vincent AD, Dalesio OB et al.Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 29, 3862–3868 (2011).
   PubMed Web of Science ®Google Scholar
• Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients–a double-blind, randomized study. Ann. Oncol. 18, 689–693 (2007).
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Pritchard KI, Loprinzi CL et al.Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J. Clin. Oncol. 28(35), 5147–5152 (2010).
   PubMedGoogle Scholar
• Speroff L, Grass M, Constantine G et al.Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet. Gynecol. 111, 77–87 (2008).
   PubMed Web of Science ®Google Scholar
• Stearns V, Isaacs C, Rowland J et al.A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. Oncol. 11, 17–22 (2000).
   PubMed Web of Science ®Google Scholar
• Stearns V, Beebe K, Iyengar M et al.Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289, 2827–2834 (2003).
   PubMed Web of Science ®Google Scholar
• Stearns V, Slack R, Greep N et al.Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J. Clin. Oncol. 23, 6919–6930 (2005).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan JA, Perez EA et al.Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20(6), 1578–1583 (2002).
   PubMed Web of Science ®Google Scholar
• Suvanto-Luukkonen E, Koivunen R, Sundström H et al.Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 12(1), 18–26 (2005).
   PubMed Web of Science ®Google Scholar
• Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 12,114–122 (2006).
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi C, Novotny P et al.Pilot evaluation of citalopram for the relief of hot flashes. J. Support Oncol. 1, 47–51 (2003).
   PubMedGoogle Scholar
• Loprinzi CL, Flynn P, Carpenter LA et al.Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J. Palliat. Med. 8, 924–930 (2005).
   PubMedGoogle Scholar
• Barton DL, LaVasseur BI, Sloan JA et al.Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J. Clin. Oncol. 28, 3278–3283 (2010).
   PubMed Web of Science ®Google Scholar
• Lash T, Pedersen L, Cronin-Fenton D et al.Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br. J. Cancer 99, 616–662 (2008).
   PubMed Web of Science ®Google Scholar
• Borges M, Desta Z, Li L et al.Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61–74 (2006).
   PubMed Web of Science ®Google Scholar
• Holzman D. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. J. Natl Cancer Inst. 101, 1370–1371(2009).
   PubMed Web of Science ®Google Scholar
• Aubert RE, Stanek EJ, Yao J et al.Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J. Clin. Oncol. 27(18 Suppl.), Abstract CRA508 (2009).
   Google Scholar
• Carpenter JS, Guthrie K, Larson JC et al.Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil. Steril. 97, 1399–1404 (2012).
   PubMed Web of Science ®Google Scholar
• Freeman EW, Guthrie KA, Caan B et al.Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 305, 267–274 (2011).
   PubMed Web of Science ®Google Scholar
• Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet. Gynecol. 101, 337–345 (2003).
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Morrow GR, Roscoe JA et al.Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366, 818–824 (2005).
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso TJr et al.Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet. Gynecol. 108, 41–48 (2006).
   PubMed Web of Science ®Google Scholar
• Presant CA, Kelly C. Palliation of vasomotor instability (hot flushes) using pregabalin. Community Oncol. 4, 83–84 (2007).
   Google Scholar
• Loprinzi CL, Qin R, Balcueva EP et al.Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J. Clin. Oncol. 28, 641–647 (2010).
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Barton DL et al.Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone. J. Clin. Oncol. 25, 308–312 (2007).
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs Arch. Pharmacol. 369, 23–37 (2004).
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V et al.CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30–39 (2005).
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L et al.Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61–74 (2006).
   PubMed Web of Science ®Google Scholar
• Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93–101 (2007).
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 32 (Suppl. 1), 1–21 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly CM, Juurlink DN, Gomes T et al.Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
   Google Scholar
• Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res. Treat. 112, 123–132 (2008).
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev. 18, 2562–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A. Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J. Clin. Pharmacol. 44, 861–865 (2004).
   PubMed Web of Science ®Google Scholar
• Sideras K, Ingle JN, Ames MM et al.Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28, 2768–2776 (2010).
   PubMed Web of Science ®Google Scholar
• Quella SK, Loprinzi CL, Barton DL et al.Evaluation of soy phytoestrogens for the treatment of hot flushes in breast cancer survivors: a North Central cancer treatment group trial. J. Clin. Oncol. 18, 1068–1074 (2000).
   PubMed Web of Science ®Google Scholar
• MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur. J. Cancer 41, 708–714 (2005).
   PubMed Web of Science ®Google Scholar
• Van Patten CL, Olivotto IA, Chambers GK et al.Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J. Clin. Oncol. 20, 1449–1455 (2002).
   PubMed Web of Science ®Google Scholar
• Nikander E, Kilkkinen A, Metsä-Heikkilä M et al.A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet. Gynecol. 101, 1213–1220 (2003).
   PubMed Web of Science ®Google Scholar
• This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 70, 222–226 (2011).
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst. Rev. (4), CD001395 (2007).
   Google Scholar
• Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int. J. Womens Health 2, 123–135 (2010).
   PubMedGoogle Scholar
• Pockaj BA, Gallagher JG, Loprinzi CL et al.Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC1. J. Clin. Oncol. 24, 2836–2841 (2006).
   PubMed Web of Science ®Google Scholar
• Geller SE, Shulman LP, van Breemen RB et al.Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 16, 1156–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Barton DL, Loprinzi CL, Quella SK et al.Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J. Clin. Oncol. 16, 495–500 (1998).
   PubMed Web of Science ®Google Scholar
• Hunter M. Cognitive behavioural interventions for premenstrual and menopausal symptoms. J. Reprod. Infant Psychol. 21, 183–193 (2003).
   Web of Science ®Google Scholar
• Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J. Psychosom. Obstet. Gynaecol. 17, 202–207 (1996).
   PubMed Web of Science ®Google Scholar
• Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 48, 97–105 (2004).
   PubMed Web of Science ®Google Scholar
• Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 19, 749–759 (2012).
   PubMed Web of Science ®Google Scholar
• Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am. J. Obstet. Gynecol. 167, 436–439 (1992).
   PubMed Web of Science ®Google Scholar
• Stevenson DW, Del Prato DJ. Multiple component self-control program for menopausal hot flashes. J. Behav. Ther. Exp. Psychiatry 14, 137–140 (1983).
   PubMed Web of Science ®Google Scholar
• Mann E, Smith MJ, Hellier J et al.Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 13, 309–318 (2012).
   PubMed Web of Science ®Google Scholar
• Duijts SF, van Beurden M, Oldenburg HS et al.Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J. Clin. Oncol. 30, 4124–4133 (2012).
   PubMed Web of Science ®Google Scholar
• Helms JM. Acupuncture Energetics: A Clinical Approach for Physicians. Medical Acupuncture Publishers, Berkeley, CA, USA (1997).
   Google Scholar
• Mittlemen E, Gayonor JS. A brief overview of the analgesic and immunologic effects of acupuncture in domestic animals. J. Am. Vet. Med. Assoc. 217, 1201–1205 (2000).
   PubMedGoogle Scholar
• Hervik J, Mjåland O. Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. Breast Cancer Res. Treat. 116, 311–316 (2009).
   PubMed Web of Science ®Google Scholar
• Liljegren A, Gunnarsson P, Landgren BM, Robéus N, Johansson H, Rotstein S. Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Res. Treat. 135, 791–798 (2012).
   PubMed Web of Science ®Google Scholar
• Nedstrand E, Wyon Y, Hammar M, Wijma K. Psychological well-being improves in women with breast cancer after treatment with applied relaxation or electro-acupuncture for vasomotor symptom. J. Psychosom. Obstet. Gynaecol. 27, 193–199 (2006).
   PubMed Web of Science ®Google Scholar
• Deng G, Vickers A, Yeung S et al.Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J. Clin. Oncol. 25, 5584–5590 (2007).
   PubMed Web of Science ®Google Scholar
• Frisk J, Carlhäll S, Källström AC, Lindh-Astrand L, Malmström A, Hammar M. Long-term follow-up of acupuncture and hormone therapy on hot flushes in women with breast cancer: a prospective, randomized, controlled multicenter trial. Climacteric 11, 166–174 (2008).
   PubMed Web of Science ®Google Scholar
• Walker EM, Rodriguez AI, Kohn B et al.Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J. Clin. Oncol. 28, 634–640 (2010).
   PubMed Web of Science ®Google Scholar
• Frisk J, Källström A, Wall N, Fredrikson M, Hammar M. Acupuncture improves health-related quality-of-life (HRQoL) and sleep in women with breast cancer and hot flushes. Support Care Cancer 20, 715–724 (2012).
   PubMed Web of Science ®Google Scholar
• Garcia MK, McQuade J, Haddad R et al.Systematic review of acupuncture in cancer care: a synthesis of the evidence. J. Clin. Oncol. 31, 952–960 (2013).
   PubMed Web of Science ®Google Scholar
• Guttuso TJr. Stellate ganglion block for treating hot flushes: a viable option or sham procedure? Maturitas (2013) (Epub ahead of print).
   PubMedGoogle Scholar
• Haest K, Kumar A, Van Calster B et al.Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann. Oncol. 23(6), 1449–1454 (2012).
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Treatment of menopause-associated menopausal symptoms: position statement of The North American Menopause Society Menopause Menopause 11(1), 11–33 (2004).
   PubMed Web of Science ®Google Scholar
• L'Espérance S, Frenette S, Dionne A, Dionne JY; Comité de l'évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 21(5), 1461–74 (2013).
   PubMedGoogle Scholar
• Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Sao Paulo Med. J. 131(2), 141 (2013).
   Google Scholar